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Abstract
Purpose The study aims to assess the relative efficacy of
granulocyte colony-stimulating factor (G-CSF) products ad-
ministered as primary prophylaxis (PP) to patients with cancer
receiving myelosuppressive chemotherapy.
Methods A systematic literature review identified publications
(January 1990 to September 2013) of randomized controlled
trials evaluating PP with filgrastim, pegfilgrastim, lenograstim,
or lipegfilgrastim in adults receiving myelosuppressive chemo-
therapy for solid tumors or non-Hodgkin lymphoma. Direct,
indirect, and mixed-treatment comparison (MTC) were used
to estimate the odds ratio and 95 % credible interval of febrile
neutropenia (FN) during cycle 1 and all cycles of chemotherapy
combined without adjusting for differences in relative dose in-
tensity (RDI) between study treatment arms.
Results Twenty-seven publications representing 30 random-
ized controlled trials were included. Using MTC over all che-
motherapy cycles, PP with filgrastim, pegfilgrastim,
lenograstim, and lipegfilgrastim versus no G-CSF PP or place-
bo were associated with statistically significantly reduced FN
risk. FN risk was also significantly reduced with pegfilgrastim
PP versus filgrastim PP. Over all chemotherapy cycles, there
was a numerical but statistically nonsignificant increase in the
FN risk for lipegfilgrastim PP versus pegfilgrastim PP. Using
MTC in cycle 1, PP with filgrastim, pegfilgrastim, and
lipegfilgrastim versus no G-CSF PP or placebo were associated
with statistically significantly reduced FN risk.
Conclusions In this meta-analysis, using MTC without ad-
justment for RDI, PP with all G-CSFs evaluated reduced the
FN risk in patients receivingmyelosuppressive chemotherapy.
Future studies are needed to assess the influence of RDI on FN
outcomes and to eliminate potential bias between G-CSF arms
receiving more intensive chemotherapy than control arms.
Keywords Meta-analysis . Pegfilgrastim . Filgrastim .
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Introduction
Febrile neutropenia (FN) is a significant dose-limiting toxicity
of myelosuppressive chemotherapy that may lead to reduced
chemotherapy relative dose intensity (RDI) and increased FN-
related morbidity and mortality [1–5]. Although there is a risk
of FN during any cycle of myelosuppressive chemotherapy,
evidence from clinical trials and observational studies sug-
gests that the greatest risk of FN is during the first cycle and
that dose reductions and delays occur most frequently in sub-
sequent cycles [2, 6–8].
Granulocyte colony-stimulating factors (G-CSFs) are gly-
coproteins that promote the growth and differentiation of
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neutrophil progenitor cells [9]. Pegfilgrastim and
lipegfilgrastim (long-acting recombinant human G-CSFs)
and filgrastim and lenograstim (short-acting recombinant hu-
man G-CSFs) are indicated to decrease the incidence of FN
and severe neutropenia, as well as the duration of neutropenia
or severe neutropenia, in patients receiving myelosuppressive
chemotherapy [10–13]. Current guidelines recommend G-
CSF primary prophylaxis (PP) when the overall risk of FN
among patients with non-myeloid malignancies receiving my-
elosuppressive chemotherapy is 20 % or greater [14–16].
Clinical trials have shown that G-CSF PP reduces the risk of
FN, chemotherapy dose delays/reductions and reduced RDI,
antibiotic use for FN-related infections, and acute FN-related
hospitalization [7, 17–23]. Meta-analyses of clinical trial data
have shown that G-CSF PP versus placebo is associated with
reduction in infection-related and all-cause mortality [5, 24].
Three applications of meta-analysis are direct comparison,
indirect comparison, and mixed-treatment comparison (MTC)
of clinical trial evidence. Direct comparison is used for esti-
mates based on direct evidence from head-to-head trials, and
indirect comparison may be used when direct evidence is un-
available and indirect evidence from randomized controlled
trials (RCTs) is being utilized. MTC is a generalized meta-
analysis that offers greater statistical power by pooling direct
and indirect evidence and assumes consistency between the
two [25]. Using direct comparison, previous meta-analyses of
RCTs have demonstrated a statistically significant reduction in
the risk of FN following either filgrastim PP or pegfilgrastim
PP versus no G-CSF, as well as pegfilgrastim PP versus
filgrastim PP [26–28]. Using direct comparison or MTC, a
statistically significant reduction in the risk of FN following
lenograstim PP versus no G-CSF was demonstrated [26].
The primary objective of this systematic review and meta-
analysis was to assess the relative efficacy of G-CSF
(filgrastim, pegfilgrastim, lenograstim, or lipegfilgrastim) PP
versus no G-CSF PP, placebo, or a comparator G-CSF product
among patients with cancer receiving chemotherapy.
Methods
Data source and search strategy
A systematic literature review was performed to identify pub-
lications of RCTs published between January 1990 and Sep-
tember 2013. Electronic databases used in the systematic re-
view were PubMed, EMBASE, Science Citation Index,
Cochrane Database of Systematic Reviews, Cochrane central
register of controlled clinical trials, Database of Abstracts of
Reviews of Effects, Health Technology Assessment Database,
and the National Health Services (NHS) Economic Evaluation
Database, and manual searches of original publications. The
search comprised subject headings and text with G-CSF
product names or synonyms combined with a search filter to
limit the results to RCTs (Online Resource 1).
Study selection and data extraction
Eligible studies included RCTs that compared PP with
filgrastim, pegfilgrastim, lenograstim, or lipegfilgrastim with
placebo, no G-CSF PP, or PP with a different G-CSF in adult
patients receiving myelosuppressive chemotherapy for solid
tumors or non-Hodgkin lymphoma. Patients initiated G-CSF
PP 1 to 3 days after completion of myelosuppressive chemo-
therapy in each cycle. Control patients could receive second-
ary prophylaxis with G-CSF after the first cycle with the same
myeloid growth factor. Studies were excluded if patients had
received granulocyte-macrophage colony-stimulating factor,
G-CSF for established FN, or different doses of the same G-
CSF in each treatment arm, and if patients had leukemia or
multiple myeloma, or bone marrow or peripheral-blood stem-
cell transplantation. Studies were also excluded if they were
economic analyses, evaluated investigational or unapproved
drugs, or were published in languages other than English.
Two independent reviewers evaluated publications identi-
fied from the search and compared them with the search
criteria to determine relevance; disagreements were resolved
by consensus [29]. Key data (e.g., protocol design and patient,
disease, and treatment characteristics) for each study were
extracted (Online Resource 2).
Study objectives
The primary objective of this study was to assess the relative
efficacy of PP with different G-CSFs in patients with cancer
who received myelosuppressive chemotherapy in RCTs by
performing meta-analyses using direct comparison, indirect
comparison, and MTC in all chemotherapy cycles without
adjustment for RDI. The secondary objective was to assess
the relative efficacy of prophylaxis with the different G-
CSFs in the first cycle of chemotherapy only. An exploratory
objective was to assess the relative efficacy of prophylaxis
with the different G-CSFs by performing a meta-regression
adjusting for RDI and other key FN risk factors as potential
confounders that could affect FN risk.
Data synthesis and analysis
The primary study effect measure was the odds ratio (OR) of FN
incidence. The treatment effects were determined using direct
and indirect comparisons (inconsistency model) and MTC (con-
sistency model), and reported as the OR (95 % credible interval
[CrI]) of FN among filgrastim PP, pegfilgrastim PP, lenograstim
PP, or lipegfilgrastim PP versus no G-CSF PP or placebo, and
among each of the four G-CSFs as PP. ORs for each study and
for conventional random-effects pairwise meta-analyses were
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calculated using Review Manager (RevMan5, Version 5.2; The
Nordic Cochrane Centre, Copenhagen, Denmark). Statistical
analyses were conducted in a Bayesian Markov chain Monte
Carlo (MCMC) framework using the WinBUGS software. Pos-
terior summaries were based on assessment of 50,000 simula-
tions following an initial 50,000 simulations to allow burn-in [26,
30]. For Bayesian analysis, priors were predefined and then up-
dated by using the data from the literature review. The resulting
treatment effects were expressed as a posterior distribution. Spe-
cifically, the prior distribution for the population mean treatment
effects was normal, with mean=0 and variance=0.0001. The
prior distribution for individual treatment had a normal (mean=
0, variance=0.0001) prior on the log OR of treatment and a
uniform distribution (0.2) prior on the standard deviation.
Direct comparison
When direct evidence was available, a random-effects model
was used for direct comparisons to estimate the OR of FN
incidence (treatment effect). Assumptions of this model are
that the treatment effects in trials for each pairwise comparison
were sampled from a random distribution of the trials. The OR
of FN incidence with G-CSF PP versus no G-CSF and with
comparisons between respective G-CSFs was assumed to be
unrelated (i.e., consistency is not assumed). The random-
effects model is equivalent to separate meta-analyses for each
relative treatment effect for head-to-head trials, except that a
common between-trials variance term was assumed.
Indirect comparison
The effect of any pair of treatments was estimated using indi-
rect evidence only. For example, the effect of C versus B (dBC)
can be obtained from the estimates of the effect of B versus A
(dAB) and the effect of C versus A (dAC): dBC=dAC−dAB. A
Bayesian two-sided P value of the null hypothesis (no differ-
ence between direct and indirect comparisons) was calculated
by estimating the proportion of iterations where the direct
estimate is larger than the indirect estimate of log OR.
Mixed treatment comparison
The MTC pooled the direct and indirect evidence to estimate
the treatment effect. The MTC model assumed a single
between-trial variance for each comparison. The OR of FN
incidence with G-CSF PP versus no G-CSF PP and between
G-CSFs assumed consistency between direct and indirect ev-
idence (dBC=dAC−dAB).
Full meta-regression analysis and treatment effect
with adjustment for RDI
In RCTs of G-CSF PP versus placebo or no G-CSF PP, che-
motherapy delays and dose reductions intended to reduce the
risk of FN can lead to variability in exposure among the treat-
ment arms, potentially resulting in significant within-study
bias in the estimated ORs. This bias, which was not consid-
ered in the previous meta-analyses conducted by Madan et al.
[26], could substantially mute the “real” clinical effect of G-
CSF, especially against placebo, and could vary between stud-
ies given differences in adherence and procedural controls of
study treatments. Thus, a meta-regression of RCTs was
planned to assess the influence of RDI and/or dose
reduction/delay on the estimated treatment effect size. The full
meta-regression was intended to assess the impact on treat-
ment effect and to assess independent variables determined as
important (e.g., cancer type, patient age, disease status [stage
of disease or limited/extensive], chemotherapy regimen,
Fig. 1 Trial publication identification and selection. The 27 included publications reported data from 30 randomized controlled trials (asterisk). Data
from three publications [32–34] were each counted as two studies
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chemotherapy regimen risk for FN [high, intermediate, or low
per National Comprehensive Cancer Network guidelines
[31]], number of cycles [maximum], cycle length, and RDI).
Evaluation of heterogeneity
Clinical heterogeneity was examined by evaluating variations
in factors such as demographic characteristics, FN definition,
cancer type, cycle length, G-CSF strategy, and allowed sample
size. Between-trial statistical heterogeneity in the random-
effects model was assessed using the Inconsistency Index (I2),
which estimates the proportion of the total variation among the
treatment effect estimates that is due to heterogeneity.
Results
Of the initial 4790 publications screened, 40 qualified for full
review. A total of 27 publications were included in the meta-
analyses, with data from 30 RCTs (Fig. 1).
Meta-analysis of all chemotherapy cycles without adjustment
for RDI
Of the 30 RCTs assessing G-CSF PP, 22 compared G-CSF PP
with no G-CSF PP or placebo, and 8 compared PP among
different G-CSFs (Fig. 2). Six RCTs compared filgrastim PP
with pegfi lgras t im PP, and two RCTs compared
lipegfilgrastim PP with pegfilgrastim PP.
The risks of FN in RCTs assessing G-CSF PP in all cycles
versus no G-CSF PP, placebo, or a different G-CSF are sum-
marized in Fig. 3. Conventional random-effects pairwise meta-
analyses were performed to calculate ORs for each trial. Het-
erogeneity among pairwise meta-analyses was moderate (I2
range 19−74 %), except for the comparisons of pegfilgrastim
PP versus filgrastim PP (I2=0) and lipegfilgrastim PP versus
placebo (not estimable; n=1 RCT).
Direct comparison
Using direct comparison, the risk of FN was statistically sig-
nificantly reduced for pegfilgrastim PP versus no G-CSF PP
or placebo (OR 0.24; 95 % CrI 0.13–0.43), filgrastim PP ver-
sus no G-CSF PP or placebo (OR 0.42; 95 % CrI 0.29–0.59),
and lenograstim PP versus no G-CSF PP or placebo (OR 0.34;
95 % CrI 0.18–0.61) (Table 1). There were no statistically
significant differences for the other comparisons.
Indirect comparison
Using indirect comparison, the risk of FN was statistically
significantly reduced for pegfilgrastim PP versus no G-CSF
PP or placebo (OR 0.26; 95 % CrI 0.13–0.55) and filgrastim
PP versus no G-CSF PP or placebo (OR 0.38; 95 % CrI 0.16–
0.93) (Table 1). There were no statistically significant differ-
ences for the other comparisons. Using a Bayesian approach,
the differences in the risk of FN between the direct and indi-
rect comparisons were not statistically significant (P>0.05)
and provided no evidence to suggest overall inconsistency.
Mixed-treatment comparison
Using MTC, the risk of FN was statistically significantly re-
duced for pegfilgrastim PP versus no G-CSF PP or placebo
Fig. 2 Overview of data from
randomized controlled trials on
G-CSF PP included in the meta-
analysis of all chemotherapy
cycles without adjustment for
relative dose intensity (n=30).
G-CSF granulocyte colony-
stimulating factor, PP primary
prophylaxis
Fig. 3 Risk of febrile neutropenia in all included trials of G-CSF PP in all
cycles (n=30). BEP/EP etoposide and cisplatin, plus or minus bleomycin;
BOP/VIP-B bleomycin, vincristine, cisplatin/etoposide, ifosfamide,
cisplatin, bleomycin; CHOP cyclophosphamide, doxorubicin,
vincristine, and prednisone; CNOP cyclophosphamide, mitoxantrone,
vincristine, and prednisone; EPAR European public assessment report;
G-CSF granulocyte colony-stimulating factor; M-H Mantel-Haenszel;
NHL non-Hodgkin lymphoma; PP primary prophylaxis
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Balducci et al 2007, NHL
Balducci et al 2007, solid tumor
Hecht et al 2010
Romieu et al 2007, cycle 1
Vogel et al 2005
Subtotal (95% CI)
Total events
Heterogeneity: Tau2=0.58; Chi2=15.11; DF=4 (P=0.004); I2=74%
Test for overall effect: Z=3.26; P=0.001
Crawford et al 1991
del Giglio et al 2008
Doorduijin et al 2003
Fosså et al 1998, BEP/EP
Fosså et al 1998, BOP/VIP-B
Osby et al 2003, CHOP
Osby et al 2003, CNOP
Pettengell et al 1992
Timmer-Bonte et al 2005
Trillet-Lenoir et al 1993
Zinzani et al 1997
Subtotal (95% CI)
Total events
Heterogeneity: Tau2=0.09; Chi2=18.48; DF=10 (P=0.05); I 2=46%
Test for overall effect: Z=6.10; P<0.00001
Bui et al 1995, cycle 1
Chevallier et al 1995
Gebbia et al 1993
Gebbia et al 1994
Gisselbrecht et al 1997
Subtotal (95% CI)
Total events
Heterogeneity: Tau2=0.05; Chi2=4.92; DF=4 (P=0.30); I 2=19%
Test for overall effect: Z=4.11; P<0.0001
Green et al 2003
Grigg et al 2003
Holmes et al 2002, phase 2
Holmes et al 2002, phase 3
Park et al 2013, cycle 1
Vose et al 2003
Subtotal (95% CI)
Total events
Heterogeneity: Tau2=0.00; Chi2=2.56; DF=5 (P=0.77); I2=0%
Test for overall effect: Z=2.15; P=0.03




Test for overall effect: Z=1.59; P=0.11
Lipeg vs peg Lonquex EPAR
Lipeg vs peg, Bondarenko et al 2013
Subtotal (95% CI)
Total events
Heterogeneity: Tau2=0.47; Chi2=1.51; DF=1 (P=0.22); I2=34%
Test for overall effect: Z=0.03; P=0.98
Total (95% CI)
Total events
Heterogeneity: Tau2=0.15; Chi2=54.13; DF=29 (P=0.003); I2=46%
Test for overall effect: Z=8.00; P<0.00001
Test for subgroup differences: Chi2=4.84; DF=5 (P=0.44); I2=0%
Primary pegfilgrastim vs no primary G-CSF / placebo
Primary filgrastim vs no primary G-CSF / placebo
Primary lenograstim vs no primary G-CSF / placebo
Primary pegfilgrastim vs primary filgrastim
Primary lipegfilgrastim vs no primary G-CSF / placebo
Primary lipegfilgrastim vs primary pegfilgrastim
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(OR 0.25; 95 % CrI 0.17–0.40), filgrastim PP versus no G-
CSF PP or placebo (OR 0.42; 95 % CrI 0.30–0.57),
lenograstim PP versus no G-CSF PP or placebo (OR 0.34;
95 % CrI 0.19–0.60), pegfilgrastim PP versus filgrastim PP
(OR 0.61; 95 % CrI 0.40–0.98), and lipegfilgrastim PP versus
no G-CSF PP or placebo (OR 0.35; 95 % CrI 0.14–0.88)
(Table 1). The risk of FN was numerically higher but statisti-
cally nonsignificant for lipegfilgrastim PP versus
pegfilgrastim PP (OR 1.39; 95 % CrI 0.54–3.50).
As expected, the values of the treatment effect estimates
using MTC, which assumed consistency, were between those
of the direct and indirect estimates. In all analyses, the root
mean square differences (direct and indirect 60.18; MTC
60.01) were consistent with the number of data points (60
study arms), indicating a lack of differentiation between the
models.
Meta-analysis of the first cycle of chemotherapy
without adjustment for RDI
Of the 30 RCTs included, 19 had available data from the first
cycle of chemotherapy (Table 2). Using MTC, FN risk in the
first cycle was statistically significantly reduced for
pegfilgrastim PP versus no G-CSF PP or placebo (OR 0.25;
95 % CrI 0.13–0.50), filgrastim PP versus no G-CSF PP or
placebo (OR 0.43; 95 % CrI 0.24–0.76), and lipegfilgrastim
PP versus no G-CSF PP or placebo (OR 0.25; 95 % CrI 0.07–
0.88). There were no statistically significant differences in the
risk of FN for the rest of the comparisons (Online Resource 3).
The results for the first cycle of chemotherapy were gener-
ally consistent with those from all cycles. The differences in
the risk of FN between the direct and indirect comparisons
were not statistically significant (P>0.05) and provided no
evidence to suggest overall inconsistency.
In all analyses, the root mean squared differences (direct
and indirect 36.44; MTC 36.26) were consistent with the
number of data points (38 study arms), indicating a lack of
differentiation between the models.
Meta-analysis of all cycles with adjustment for RDI
A minimum of 10 studies for each study-level variable has
been suggested as the lowest number of studies for meta-
regression [50, 51]. In this study, the meta-regression analysis
adjusting for RDI could not be conducted because only 10
RCTs overall (8 comparing filgrastim PP versus no G-CSF
and 2 comparing lenograstim PP versus no G-CSF) contained
RDI information that could be included in the model (Table 2
and Online Resource 4).
Full meta-regression of all cycles
The explanatory variables in the studies used for the meta-
regression analysis are described in Online Resource 4. There
was insufficient reporting of most of the variables predictive
of FN risk within trials needed to conduct a full meta-
regression; age was the most commonly and consistently re-
ported variable.
Discussion
G-CSF PP has been shown to reduce the risk of FN and FN-
related hospitalization in patients receiving myelosuppressive
chemotherapy for cancer [7, 16–21]. The reduction in FN
incidence by G-CSF, however, can potentially be confounded
by the delays in chemotherapy administration and the reduced
dosing of chemotherapy that are intended to reduce the risk of
FN. These delays and dose reductions often result in lower
chemotherapy RDI in the control arm of RCTs and may lead
to an underestimation of the potential treatment effect. Sec-
ondary prophylaxis after the first cycle of chemotherapy in
Table 1 Posterior odds ratios for febrile neutropenia from all cycles with and without the assumption of consistency (30 trials, 60 arms)
Treatment contrasta Consistency not assumed Consistency assumed
Direct OR (95 % CrI) Indirect OR (95 % CrI) P valueb Combined (MTC) OR (95 % CrI)
Pegfilgrastim PP vs no G-CSF PP or placebo 0.24 (0.13–0.43) 0.26 (0.13–0.55) 0.58 0.25 (0.17–0.40)
Filgrastim PP vs no G-CSF PP or placebo 0.42 (0.29–0.59) 0.38 (0.16–0.93) 0.42 0.42 (0.30–0.57)
Lenograstim PP vs no G-CSF PP or placebo 0.34 (0.18–0.61) N/A N/A 0.34 (0.19–0.60)
Pegfilgrastim PP vs filgrastim PP 0.63 (0.33–1.22) 0.57 (0.29–1.15) 0.42 0.61 (0.40–0.98)
Lipegfilgrastim PP vs no G-CSF PP or placebo 0.48 (0.13–1.74) 0.24 (0.06–1.02) 0.24 0.35 (0.14–0.88)
Lipegfilgrastim PP vs pegfilgrastim PP 1.00 (0.26–3.79) 2.00 (0.47–8.11) 0.76 1.39 (0.54–3.50)
Bayesian methods used to obtain meta-analysis data
CrI credible interval, G-CSF granulocyte colony-stimulating factor, MTC mixed-treatment comparison, N/A not available, OR odds ratio, PP primary
prophylaxis
aMedian OR values are shown unless indicated otherwise
b Bayesian P value determined based on comparison of direct and indirect evidence
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RCTs may also diminish the estimates of G-CSF treatment
effects. Because of the potential for such bias, this meta-
analysis was designed to assess the risk of FN during the first
chemotherapy cycle, as well as across all cycles.
There were several notable findings in this meta-analysis.
First, there was a significant reduction in FN risk following
PP with pegfilgrastim, filgrastim, or lenograstim compared
with controls, confirming the results of previous meta-
analyses [26–28]. Second, in contrast with the meta-analysis
by Madan et al. [26], our MTC demonstrated a statistically
significant reduction in FN risk for pegfilgrastim PP versus
filgrastim PP. This difference may be due to the inclusion in
the current analysis of an additional RCT that compared
filgrastim to a biosimilar of pegfilgrastim [47]. Third, using
MTC, there was a statistically significant reduction in FN risk
with lipegfilgrastim versus placebo. Fourth, theMTC showed a
numerically higher but not statistically significant likelihood of
FN reduction in favor of pegfilgrastim versus lipegfilgrastim.
Finally, consistent with the results across all chemotherapy cy-
cles, the MTC showed that PP with pegfilgrastim, filgrastim,
and lipegfilgrastim significantly reduced the risk of FN during
the first cycle of chemotherapy. The relatively small sample of
studies that met inclusion criteria for the MTC (n=19) may
explain the convergent results and wide CrIs when compared
with the result of the MTC analysis of objective 1 (all chemo-
therapy cycles without adjustment for RDI).
Only three studies provided direct evidence for the effec-
tiveness of lipegfilgrastim PP [49]: lipegfilgrastim PP versus
Table 2 Included studies and data reported for chemotherapy cycle and relative dose intensity
Study All cycles First cycle RDI information Meta-regression
Balducci et al. 2007 (NHL) [32] ✓ ✓
Balducci et al. 2007 (solid tumor) [32] ✓ ✓
Hecht et al. 2010 [22] ✓
Romieu et al. 2007 (cycle 1) [35] ✓ ✓
Vogel et al. 2005 [7] ✓ ✓
Crawford et al. 1991 [17] ✓ ✓
del Giglio et al. 2008 [36] ✓ ✓
Doorduijin et al. 2003 [37] ✓ ✓
Fosså et al. 1998 (BEP/EP) [33] ✓ ✓
Fosså et al. 1998 (BOP/VIP-B) [33] ✓ ✓
Osby et al. 2003 (CHOP) [34] ✓ ✓ ✓
Osby et al. 2003 (CNOP) [34] ✓ ✓ ✓
Pettengell et al. 1992 [19] ✓ ✓
Timmer-Bonte et al. 2005 [38] ✓ ✓
Trillet-Lenoir et al. 1993 [39] ✓ ✓ ✓
Zinzani et al. 1997 [40] ✓ ✓
Bui et al. 1995 (cycle 1) [41] ✓ ✓
Chevallier et al. 1995 [42] ✓
Gebbia et al. 1993 [43] ✓ ✓
Gebbia et al. 1994 [44] ✓
Gisselbrecht et al. 1997 [18] ✓ ✓
Green et al. 2003 [21] ✓ ✓
Grigg et al. 2003 [45] ✓ ✓
Holmes et al. 2002 (phase 2) [46] ✓ ✓
Holmes et al. 2002 (phase 3) [20] ✓ ✓
Park et al. 2013 (cycle 1) [47] ✓ ✓
Vose et al. 2003 [48] ✓
Lonquex EPAR 2013 (lipegfilgrastim vs placebo) [49] ✓ ✓
Lonquex EPAR 2013 (lipegfilgrastim vs pegfilgrastim) [49] ✓ ✓
Bondarenko et al. 2013 [23] ✓ ✓
Additional information on these studies is provided in Online Resource 4
BEP/EP etoposide and cisplatin, plus or minus bleomycin; BOP/VIP-B bleomycin, vincristine, cisplatin/etoposide, ifosfamide, cisplatin, and bleomycin;
CHOP cyclophosphamide, doxorubicin, vincristine, and prednisone; CNOP cyclophosphamide, mitoxantrone, vincristine, and prednisone; EPAR
European public assessment report; NHL non-Hodgkin lymphoma; RDI relative dose intensity.
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pegfilgrastim PP in a phase 2 and a phase 3 study in breast
cancer patients receiving doxorubicin and docetaxel, and
lipegfilgrastim versus placebo in a phase 3 study in patients
with non−small-cell lung cancer receiving cisplatin/etoposide
[49]. More evidence is required for lipegfilgrastim PP given
the relatively limited number of studies, tumor types, and che-
motherapy agents on the treatment effect of lipegfilgrastim PP
and given the lack of significant findings in the placebo-
controlled study [49].
One of the goals of this meta-analysis was to assess the
impact of chemotherapy RDI on RCT treatment effect esti-
mates and challenge the assumptions that the consistency of
treatment effects is reasonable. It is possible that heterogeneity
exists between the included studies and that the individual
treatment effects were biased because of factors such as
study-related imbalances in delivered dose intensity and num-
ber of chemotherapy cycles. The inability to adjust our anal-
yses for RDI and other key factors affecting FN because of
insufficient data highlights the need for more complete
reporting of RDI in clinical trials, which would allow a more
adequate assessment of the assumptions of consistency in the
models used. Others have reported on some of these limita-
tions in oncology studies, including reporting of drug use,
outcomes, and other critical data that are required to justify
assumptions of consistency and heterogeneity [24, 27, 28].
Although Cochrane Collaborations states that direct evi-
dence should have a higher rating in the evidence hierarchy
than indirect evidence [50], it is challenging to construct a
coherent and internally consistent analysis for multiple treat-
ments based on incremental effect size. To model variation
between trials, the Bayesian MCMC method allowed us to
fit a random-effects model assuming an independent normal
distribution for relative treatment effect (log OR) and homo-
geneous variance (σ2) across all treatments. This is a reason-
able model under the assumption that the evidence for all
treatment comparisons is homogeneous.
This systematic review and meta-analysis had several lim-
itations. Publications that were not indexed would not have
been captured, potentially reducing the number of included
trials. Although unlikely in the current study based on the
existing state of knowledge for G-CSF PP, publication bias
may have occurred if the published research was systemati-
cally unrepresentative of the population of completed studies.
Unreported differences among studies (e.g., treatment alloca-
tion, blinding, and handling of withdrawals) may have biased
the results of the study, possibly limiting the extent of gener-
alization between study results. Because patient-level infor-
mation was not available, outcomes of individual patients
could not be reclassified to a common definition of FN, po-
tentially increasing trial heterogeneity in the meta-analysis.
Although unrelated to the study selection process, patients in
control arms may have received secondary prophylaxis with
G-CSF in later cycles or had changes in treatments (e.g.,
chemotherapy dose reductions), potentially biasing the report-
ed treatment effect of a G-CSF. Finally, the planned meta-
regression analysis including RDI and other patient-level FN
risk factors could not be performed because of an insufficient
number of trials reporting patient-level data or reporting the
data in a homogeneous manner for pooled analysis.
In conclusion, this meta-analysis confirmed previous ob-
servations [26–28] that G-CSF PP reduces the risk of FN in
patients receiving myelosuppressive chemotherapy. The risk
of FN was reduced with pegfilgrastim PP, filgrastim PP,
lenograstim PP, and lipegfilgrastim PP when compared with
no G-CSF PP or placebo. Additionally, compared with
filgrastim PP, pegfilgrastim PP significantly reduced FN risk
(OR=0.61; 95 % CrI 0.40–0.98). Over all chemotherapy cy-
cles, there was a numerically higher but statistically nonsig-
nificant increase in the FN risk for lipegfilgrastim PP versus
pegfilgrastim PP (OR 1.39; 95 % CrI 0.54–3.50); a statistical-
ly significant difference was not expected because of the small
sample size (n=306) for lipegfilgrastim (two studies). The
effectiveness of G-CSF PP in preventing FN may have been
underestimated because of various confounding factors in-
cluding differences in received chemotherapy RDI between
treatment arms and differences in the treatment approaches
by healthcare practitioners. Given that reduced chemotherapy
RDI is a risk factor for the development of FN and ultimately
influences patient outcomes, it is important that patient-level
data on RDI be reported in future studies assessing G-CSF PP,
particularly because of the potential for confounding due to
differences in RDI between treatment groups.
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